CYTENA and ExcellGene to develop automated workflows for biotherapeutics cell line development
CYTENA, a BICO group company and a leading provider of high-precision instruments for handling biological cells, has entered a collaboration agreement with ExcellGene SA, a leading biologics Contract Development & Manufacturing Organization (CDMO) that manufactures recombinant proteins. Together, the companies will streamline cell line development workflows for highly-efficient monoclonal antibody (mAb) and complex therapeutic protein manufacturing which enables important improvements to the development workflows of the biopharmaceutical industry.
As part of the collaboration, ExcellGene is providing its high-performance CHOExpress system, a high-yield mammalian host cell line for large-scale manufacturing of therapeutic proteins. CYTENA will establish workflows on the new C.STATION – a next generation automated workstation for Cell Line Development. The first C.STATIONs will be installed at CYTENA’s biopharmaceutical customers within the next few months. Delivering improved workflows with the C.STATION will lead to an even higher demand for this fully automated solution in therapeutic protein manufacturing.
“I am thrilled to announce this exciting collaboration,” said Dr Julian Riba, CEO of CYTENA. “This will allow us to establish more efficient protocols for stable CHO Cell Line Development (CLD) on our new platform. And it brings us one step further in our mission to make the production of biotherapeutic proteins faster, safer, and more affordable.”
Fully automated cell line development (CLD) from cloning single cells to the selection of high-producing clones for upscaling, has long been a goal of CDMOs like ExcellGene. CYTENA now offers a next-generation CLD platform for reducing timelines, eliminating contamination and improving cell viability in an all-in-one intuitive workstation.
